walk
author
specul
differ
bodi
postur
function
residu
capac
andor
hemodynam
probabl
caus
find
abil
fix
arm
posit
handlebar
may
improv
accessori
muscl
use
manner
improv
respiratori
effici
bicycl
author
conclud
cycl
may
reflect
precis
ventilatori
metabol
requir
daili
activ
walk
current
studi
anoth
recent
investig
confirm
arteri
desatur
like
occur
maxim
cycl
whether
walk
cycl
correctli
demonstr
physiolog
abnorm
exercis
sever
copd
realli
matter
patient
copd
ride
bicycl
nearli
walk
summari
turner
et
al
ad
understand
evalu
dyspneic
copd
patient
compar
iswt
cycl
ergometri
test
group
substanti
airflow
obstruct
popul
three
act
maxim
test
walk
test
like
identifi
oxygen
desatur
easiest
perform
mani
situat
adequ
test
although
treadmil
test
may
necessari
specif
applic
mention
birmingham
al
singapor
juli
world
health
organ
announc
last
known
chain
humantohuman
transmiss
sar
broken
taiwan
brought
end
initi
outbreak
sar
begun
midnovemb
southern
china
spread
intern
late
februari
genet
analysi
show
sar
coronaviru
cov
isol
guangzhou
share
origin
countri
phylogenet
pathway
match
spread
sar
part
world
juli
probabl
case
report
countri
region
death
toll
due
limit
knowledg
newli
emerg
diseas
treatment
sar
empir
outbreak
apart
support
care
appropri
treatment
sar
unknown
present
prospect
random
placebocontrol
studi
intervent
report
respiratori
failur
major
complic
sar
hypoxemia
develop
almost
half
affect
adult
adult
may
requir
icu
admiss
wherea
adult
may
progress
ard
necessit
use
invas
ventilatori
support
anecdot
report
indic
noninvas
positivepressur
ventil
nppv
effect
sar
patient
respiratori
failur
current
issu
chest
see
page
cheung
et
al
report
efficaci
safeti
nppv
treatment
acut
respiratori
failur
occur
phase
sar
nppv
appli
via
face
mask
patient
develop
sever
acut
hypoxem
respiratori
failur
without
preexist
copd
hospit
environ
adequ
airflow
full
person
protect
equip
addit
viralbacteri
filter
exhal
port
nppv
devic
endotrach
intub
avoid
patient
much
shorter
length
stay
icu
intub
healthcar
worker
hcw
particularli
vulner
sarscov
viral
load
increas
peak
level
day
diseas
onset
thu
major
concern
use
nppv
whether
clinic
subclin
sarscov
infect
among
hcw
involv
manag
patient
none
hcw
involv
develop
clinic
evid
sar
wherea
hcw
neg
sar
serolog
still
three
hcw
refus
sar
serolog
test
one
entir
elimin
possibl
subclin
sar
infect
relat
use
nppv
although
seem
highli
unlik
howev
report
wild
anim
handler
southern
china
may
develop
posit
antibodi
sarscov
without
symptom
despit
retrospect
natur
studi
small
sampl
size
lack
control
group
author
commend
ad
evid
applic
nppv
respiratori
failur
relat
communityacquir
pneumonia
cap
confalonieri
et
al
report
nppv
lower
intub
rate
length
icu
stay
mortal
rate
patient
sever
cap
benefici
action
confin
patient
underli
copd
prospect
observ
studi
exclud
patient
underli
copd
jolliet
et
al
show
nppv
improv
oxygen
respiratori
rate
patient
cap
initi
trial
patient
need
intub
averag
day
mainli
worsen
respiratori
failur
nppv
welltoler
sar
patient
probabl
sputum
product
uncommon
patient
sarscov
pneumonia
nevertheless
nppv
appli
adequ
protect
hcw
ie
adequ
air
exchang
contact
droplet
precaut
plu
full
person
protect
equip
potenti
risk
viral
transmiss
via
mask
leakag
flow
compens
caus
dispers
contamin
aerosol
cheung
et
al
shown
nppv
may
reduc
intub
rate
number
icu
admiss
appli
earli
sar
patient
sever
acut
hypoxem
respiratori
failur
addit
viralbacteri
filter
exhal
port
nppv
oxygen
mask
may
reduc
risk
nosocomi
transmiss
sar
ribavirin
nucleosid
analog
activ
number
virus
vitro
wide
use
treatment
sar
last
year
week
ribavirin
treatment
patient
experienc
fall
hemoglobin
level
gdl
baselin
wherea
evid
hemolyt
anemia
document
patient
use
ribavirin
treatment
sar
toronto
base
higher
dosag
use
treat
hemorrhag
fever
viru
associ
toxic
includ
elev
level
transaminas
bradycardia
nevertheless
ribavirin
signific
vitro
activ
sarscov
genom
analysi
sarscov
reveal
sever
type
enzymat
target
includ
proteas
chu
et
al
demonstr
vitro
activ
sarscov
lopinavir
ribavirin
gml
respect
h
incub
cytopath
inhibit
achiev
concentr
gml
lopinavir
combin
gml
ribavirin
suggest
combin
might
synergist
sarscov
vivo
two
retrospect
match
cohort
studi
compar
clinic
outcom
patient
receiv
lopinavir
mg
ritonavir
mg
lpvr
kaletra
abbott
laboratori
abbott
park
il
addit
ribavirin
either
initi
therapi
within
day
onset
symptom
rescu
therapi
puls
methylprednisolon
mp
treatment
worsen
respiratori
symptom
vs
histor
control
subject
receiv
ribavirin
alon
initi
antivir
therapi
addit
lpvr
initi
therapi
associ
reduc
overal
death
rate
intub
rate
compar
match
cohort
receiv
standard
treatment
respect
benefici
effect
includ
reduct
mp
use
fewer
nosocomi
infect
decreas
viral
load
rise
peripher
lymphocyt
count
howev
subgroup
receiv
lpvr
rescu
therapi
better
match
cohort
receiv
higher
mean
dose
mp
improv
clinic
outcom
patient
receiv
lpvr
part
initi
therapi
may
due
fact
peak
serum
concentr
lopinavir
gml
trough
serum
concentr
lopinavir
gml
could
inhibit
viru
phase
sar
progress
pneumonia
hypoxemia
iv
puls
mp
g
daili
given
prevent
immunopatholog
lung
injuri
rational
progress
pulmonari
diseas
may
mediat
host
inflammatori
respons
use
puls
mp
clinic
progress
associ
favor
clinic
improv
resolut
fever
lung
opac
within
week
corticosteroid
use
therapi
ct
scan
thorax
reveal
radiolog
featur
bronchiol
obliteran
organ
pneumonia
steroidrespons
condit
presenc
suggest
immunolog
phenomenon
pulmonari
patholog
featur
domin
diffus
alveolar
damag
presenc
multinucl
pneumocyt
bronchiol
obliteran
organ
pneumonialik
lesion
subpleur
locat
also
seen
use
highdos
puls
mp
therapi
aim
suppress
cytokineinduc
lung
injuri
phase
sar
wong
et
al
demonstr
mark
elev
helper
type
cytokin
interferon
ifn
inflammatori
cytokin
interleukin
il
least
week
sar
onset
chemokin
profil
demonstr
signific
elev
monocyt
chemoattract
induc
corticosteroid
significantli
reduc
monocyt
chemoattract
induc
concentr
day
treatment
data
confirm
helper
type
cellmedi
immun
hyperinn
inflammatori
respons
patient
sar
accumul
monocytesmacrophag
neutrophil
addit
patient
fatal
sar
macrophag
promin
leukocyt
present
alveoli
evid
hemophagocytosi
lung
hemophagocytosi
attribut
cytokin
dysregul
intervent
steroid
might
modul
cytokin
respons
prevent
fatal
outcom
propos
caus
ard
howev
retrospect
analysi
show
use
puls
corticosteroid
associ
increas
risk
mortal
studi
could
establish
whether
causal
relationship
exist
use
puls
corticosteroid
increas
risk
death
nevertheless
prolong
corticosteroid
therapi
could
increas
risk
complic
dissemin
fungal
diseas
avascular
necrosi
bone
optim
dose
time
durat
corticosteroid
administr
requir
investig
type
ifn
like
produc
earli
part
innat
immun
respons
viral
infect
type
ifn
inhibit
wide
rang
rna
dna
virus
includ
sar
cov
vitro
uncontrol
studi
toronto
use
ifn
plu
corticosteroid
associ
improv
oxygen
satur
rapid
resolut
radiograph
lung
opac
lower
level
creatinin
kinas
complet
inhibit
cytopath
effect
sarscov
cultur
observ
ifn
subtyp
human
leukocyt
experiment
infect
cynomolgu
macaqu
sarscov
prophylact
treatment
pegyl
significantli
reduc
viral
replic
excret
viral
antigen
express
type
pneumocyt
pulmonari
damag
compar
untreat
macaqu
wherea
postexposur
treatment
pegyl
yield
intermedi
result
find
support
clinic
test
approv
ifn
treatment
sar
sever
treatment
modal
deserv
investig
glycyrrhizin
activ
compon
liquoric
root
activ
inhibit
sarscov
vitro
convalesc
plasma
donat
patient
recov
sar
contain
neutral
antibodi
may
clinic
use
treat
sar
patient
adenovirusbas
vaccin
induc
strong
sarscovspecif
immun
respons
rhesu
macaqu
hold
promis
develop
protect
vaccin
sarscov
evid
sarscov
infect
initi
bind
protein
angiotensinconvert
receptor
highaffin
human
monoclon
antibodi
humab
identifi
use
sarscov
protein
term
potent
neutral
activ
vitro
vivo
humab
effici
neutral
sarscov
inhibit
syncytia
format
cell
express
protein
express
sarscov
receptor
angiotensinconvert
humab
may
use
viral
entri
inhibitor
emerg
prophylaxi
treatment
sar
earli
laboratori
confirm
sar
facilit
earli
isol
patient
reduc
risk
nosocomi
transmiss
detect
rate
sarscov
urin
sampl
nasopharyng
aspir
stool
specimen
use
convent
revers
transcriptas
polymeras
chain
reaction
rtpcr
gener
low
first
week
ill
wherea
serolog
confirm
may
take
day
reach
detect
rate
optim
rna
extract
method
appli
quantit
realtim
rtpcr
techniqu
sensit
nasopharyng
aspir
specimen
earli
diagnosi
sar
enhanc
first
day
quantit
measur
blood
sarscov
rna
realtim
rtpcr
techniqu
develop
detect
rate
first
week
infect
one
year
elaps
sinc
global
outbreak
spread
sar
intern
travel
despit
reemerg
sar
involv
laboratori
personnel
singapor
taiwan
recent
four
resid
guangdong
major
outbreak
secondari
spread
occur
howev
one
never
complac
deal
emerg
infecti
diseas
random
placebocontrol
studi
differ
treatment
modal
must
place
sar
return
